关注
Xun Tao
Xun Tao
在 gene.com 的电子邮件经过验证
标题
引用次数
引用次数
年份
First penicillin-binding protein occupancy patterns of β-lactams and β-lactamase inhibitors in Klebsiella pneumoniae
DS Sutaria, B Moya, KB Green, TH Kim, X Tao, Y Jiao, A Louie, ...
Antimicrobial agents and chemotherapy 62 (6), 10.1128/aac. 00282-18, 2018
852018
High-dose ampicillin-sulbactam combinations combat polymyxin-resistant Acinetobacter baumannii in a hollow-fiber infection model
JR Lenhard, NM Smith, ZP Bulman, X Tao, V Thamlikitkul, BS Shin, ...
Antimicrobial Agents and Chemotherapy 61 (3), 10.1128/aac. 01268-16, 2017
782017
Polymyxin-resistant, carbapenem-resistant Acinetobacter baumannii is eradicated by a triple combination of agents that lack individual activity
JR Lenhard, V Thamlikitkul, FP Silveira, SM Garonzik, X Tao, A Forrest, ...
Journal of Antimicrobial Chemotherapy 72 (5), 1415-1420, 2017
602017
Determining the optimal dosing of a novel combination regimen of ceftazidime/avibactam with aztreonam against NDM-1-producing Enterobacteriaceae using a hollow-fibre infection …
TP Lodise, NM Smith, N O’Donnell, AE Eakin, PN Holden, ...
Journal of Antimicrobial Chemotherapy 75 (9), 2622-2632, 2020
592020
Zika virus replication is substantially inhibited by novel favipiravir and interferon alpha combination regimens
CP Pires de Mello, X Tao, TH Kim, JB Bulitta, JL Rodriquez, JJ Pomeroy, ...
Antimicrobial Agents and Chemotherapy 62 (1), 10.1128/aac. 01983-17, 2018
362018
Comparable efficacy and better safety of double β-lactam combination therapy versus β‑lactam plus aminoglycoside in gram-negative bacteria in randomized, controlled trials
Y Jiao, B Moya, MJ Chen, AP Zavascki, H Tsai, X Tao, DS Sutaria, ...
Antimicrobial Agents and Chemotherapy 63 (7), 10.1128/aac. 00425-19, 2019
312019
Clinical regimens of favipiravir inhibit Zika virus replication in the hollow-fiber infection model
CP Pires de Mello, X Tao, TH Kim, M Vicchiarelli, JB Bulitta, A Kaushik, ...
Antimicrobial agents and chemotherapy 62 (9), 10.1128/aac. 00967-18, 2018
262018
First penicillin-binding protein occupancy patterns for 15 β-lactams and β-lactamase inhibitors in Mycobacterium abscessus
ARM Sayed, NR Shah, KB Basso, M Kamat, Y Jiao, B Moya, DS Sutaria, ...
Antimicrobial agents and chemotherapy 65 (1), 10.1128/aac. 01956-20, 2020
212020
Novel cassette assay to quantify the outer membrane permeability of five β-lactams simultaneously in carbapenem-resistant Klebsiella pneumoniae and Enterobacter cloacae
TH Kim, X Tao, B Moya, Y Jiao, KB Basso, J Zhou, Y Lang, DS Sutaria, ...
MBio 11 (1), 10.1128/mbio. 03189-19, 2020
182020
Four decades of β-lactam antibiotic pharmacokinetics in cystic fibrosis
JB Bulitta, Y Jiao, SK Drescher, A Oliver, A Louie, B Moya, X Tao, ...
Clinical Pharmacokinetics 58, 143-156, 2019
172019
Combating multidrug‐resistant bacteria by integrating a novel target site penetration and receptor binding assay platform into translational modeling
Y Lang, NR Shah, X Tao, SM Reeve, J Zhou, B Moya, ARM Sayed, ...
Clinical Pharmacology & Therapeutics 109 (4), 1000-1020, 2021
122021
Mechanistic insights to combating NDM-and CTX-M-coproducing Klebsiella pneumoniae by targeting cell wall synthesis and outer membrane integrity
NM Smith, KR Boissonneault, L Chen, V Petraitis, R Petraitiene, X Tao, ...
Antimicrobial agents and chemotherapy 66 (9), e00527-22, 2022
112022
Novel population pharmacokinetic approach to explain the differences between cystic fibrosis patients and healthy volunteers via protein binding
NR Shah, JB Bulitta, M Kinzig, CB Landersdorfer, Y Jiao, DS Sutaria, ...
Pharmaceutics 11 (6), 286, 2019
102019
Novel cassette assay to quantify the outer membrane permeability of five beta-lactams simultaneously in carbapenem-resistant Klebsiella pneumoniae and Enterobacter cloacae …
TH Kim, X Tao, B Moya, Y Jiao, KB Basso, J Zhou, Y Lang, DS Sutaria, ...
82020
First population pharmacokinetic analysis showing increased quinolone metabolite formation and clearance in patients with cystic fibrosis compared to healthy volunteers
Y Jiao, TH Kim, X Tao, M Kinzig, CB Landersdorfer, SK Drescher, ...
European Journal of Pharmaceutical Sciences 123, 416-428, 2018
82018
Combination regimens of favipiravir plus interferon alpha inhibit chikungunya virus replication in clinically relevant human cell lines
EJ Franco, X Tao, KC Hanrahan, J Zhou, JB Bulitta, AN Brown
Microorganisms 9 (2), 307, 2021
72021
Mini-PBPK-based population model and covariate analysis to assess the complex pharmacokinetics and pharmacodynamics of RO7449135, an Anti-KLK5/KLK7 bispecific antibody in …
H Cai, X Tao, J Shim, RN Bauer, M Bremer, W Bu, J LaMar, R Basile, ...
The AAPS Journal 25 (4), 64, 2023
42023
Favipiravir Suppresses Zika Virus (ZIKV) through Activity as a Mutagen
EJ Franco, E Cella, X Tao, KC Hanrahan, T Azarian, AN Brown
Microorganisms 11 (5), 1342, 2023
42023
Comparable bioavailability and disposition of pefloxacin in patients with cystic fibrosis and healthy volunteers assessed via population pharmacokinetics
JB Bulitta, Y Jiao, CB Landersdorfer, DS Sutaria, X Tao, E Shin, R Höhl, ...
Pharmaceutics 11 (7), 323, 2019
42019
Exploring How Antibody Format Drives Clearance from the Brain
K Schwinghamer, BM Kopec, E Ayewoh, X Tao, S Sadekar, A Sreedhara, ...
Molecular Pharmaceutics 21 (9), 4416-4429, 2024
2024
系统目前无法执行此操作,请稍后再试。
文章 1–20